Benign prostatic hyperplasia treatment market value to reach $5 billion by 2024

17 September 2015  •  Author: Victoria White

The value of the global therapeutics market for benign prostatic hyperplasia will rise from just over $2 billion in 2014 to approximately $4.9 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 8.23%, according to research and consulting firm GlobalData.


The Company’s latest report, OpportunityAnalyzer: Benign Prostatic Hyperplasia – Opportunity Analysis and Forecast to 2024, states that across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, the US will continue its current dominance, accounting for 65% of the global arena by 2024.

Valentina Gburcik, Ph.D., GlobalData’s Director of Cardiovascular & Metabolic Disorders, states that three novel therapies will contribute to the growth of the benign prostatic hyperplasia therapeutics market, including the launch of Nymox’s novel first-in-class therapy, NX-1207, in the US and Europe in 2017 and 2019, respectively.

Gburcik said,“NX-1207 is a direct prostatic injection indicated for patients with moderate-to-severe BPH. It offers an increased safety profile and improved efficacy in comparison with currently available BPH therapies, and lasts for a mean duration of 3.5 years after a single injection.

“The drug will also be priced at a premium compared with current products, meaning that it will contribute significantly towards the anticipated market expansion following its launch.”

Increase in number of diagnosed benign prostatic hyperplasia cases driving the market

The director adds that an increasing number of diagnosed benign prostatic hyperplasia cases worldwide, resulting from an aging male population, will further drive the market over the forecast period.

However, several barriers will hinder any further growth in the benign prostatic hyperplasia therapy space, according to GlobalData’s report.

Gburcik explained, “By the end of 2024, various key benign prostatic hyperplasia treatments, such as Jalyn, Avodart, Rapaflo and Cialis, will see their patents expire, followed by subsequent generic erosion.

“This will be exacerbated by a lack of pipeline therapies for mild-to-moderate benign prostatic hyperplasia symptoms, leaving a significant portion of the patient population underserved.”

Comments are closed.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...